PRESENTATION
A 59-year-old gentleman with a history of patchy alopecia areata presented with sudden onset alopecia totalis/universalis within 2 weeks after discontinuing telaprevir, peg-interferon alfa-2a, and ribavirin therapy for chronic hepatitis C.
HISTORY
He was diagnosed with hepatitis C at the age of 17 years, but his disease progressed, prompting treatment with triple therapy. He also had a history of hyperthyroidism possibly due to Graves' disease, which had been stable for 15 years on methimazole, and a history of epilepsy well controlled on lamotrigine for about 10 years. He had a history of allergic rhinitis as well. Before starting triple therapy, the thyroid was destroyed through radioablation.
The patient was treated for a total of 6 months. During the first 3 months, he was on all three medications, then peg-interferon-alfa-2a and ribavirin were continued for an additional 3 months. He reported a slight diffuse increase in hair shedding throughout therapy but no clear patches. He was not evaluated by dermatology at that time. Of note, he was hospitalized for sepsis about 3 months into the treatment. After completing the therapy, he reported rapid hair loss in clumps, which ended in near complete loss of hair on the scalp, eyebrows, eyelashes, and beard. He retains some body hair. Four months after completing triple therapy, he presented to dermatology clinic noting no significant hair regrowth.
EXAMINATION
On examination, he had scattered white and gray terminal hairs on the scalp and complete eyebrow, eyelash, and beard loss with no evidence of scarring. There were a few patches of non-scarring alopecia on the upper and lower extremities.
INVESTIGATIONS, MANAGEMENT, AND OUTCOME
Thyroid function tests were within normal limits. Antinuclear antibody waso1:40. The patient has declined treatment.
DISCUSSION
Interferon-alfa treatment, with and without ribavirin, has been linked to the exacerbation or onset of several autoimmune conditions, including thyroid disorders and insulin-dependent diabetes as well as hair loss, including patchy alopecia areata, telogen effluvium, and injection site alopecia (Tosti et al., 1992; Kartal et al., 2007) . Telaprevir is a newer protease inhibitor, which is associated with a severe and characteristic rash but has not been associated with alopecia of any type. Five cases of alopecia totalis or universalis during peg-interferon alfa-2a and ribavirin therapy for chronic hepatitis C have been reported in the literature CASE REPORT (Taliani et al., 2005 , Demirturk et al., 2006 Kartal et al., 2007; Shafa et al., 2010) (Table 1 ). All cases except one showed complete regrowth within about 1 year of discontinuing therapy. One patient had been treated with interferon-alfa monotherapy in the past with associated alopecia of unknown type (Shafa et al., 2010) . This case stands out as the first reported case with a previous history of alopecia areata unrelated to interferon, and the first to have onset after therapy was discontinued. These cases represent a striking adverse event with significant clinical implications for patients undergoing treatment for chronic hepatitis C. The immunological implications regarding the role of interferon alpha in triggering alopecia areata onset, recurrence, and/or progression outside the context of hepatitis C is also of great interest and could elucidate some of the mechanisms behind this common disease.
